QBFM
ENTA icon

QS Batterymarch Financial Management’s Enanta Pharmaceuticals ENTA Stock Holding History

QS Batterymarch Financial Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3.36M Buy
84,971
+2,558
+3% +$102K 0.09% 326
2014
Q2 		$3.55M Buy
82,413
+22,613
+38% +$863K 0.09% 345
2014
Q1 		$2.39M Buy
+59,800
New +$2.17M 0.05% 461

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

QS Batterymarch Financial Management's ENTA Position: Q3 2014 in Review

QS Batterymarch Financial Management increased its Enanta Pharmaceuticals (ENTA) stake by 3.1% in Q3 2014, buying an estimated $102K and bringing the position to 84,971 shares worth $3.36M. The position accounts for 0.09% of the portfolio, ranked #326.

QS Batterymarch Financial Management first reported a position in ENTA in Q1 2014 and has held it in 3 quarters since. The position peaked at $3.55M in Q2 2014. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2014.

  • QS Batterymarch Financial Management held 84,971 shares of Enanta Pharmaceuticals worth $3.36M as of Q3 2014.
  • QS Batterymarch Financial Management bought 2,558 Enanta Pharmaceuticals shares in Q3 2014, an estimated $102K.
  • Enanta Pharmaceuticals made up 0.09% of QS Batterymarch Financial Management's portfolio in Q3 2014, its #326 holding.
  • QS Batterymarch Financial Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 3 quarters since.
  • QS Batterymarch Financial Management's Enanta Pharmaceuticals position peaked at $3.55M in Q2 2014.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2014.

Based on QS Batterymarch Financial Management's 13F filing for Q3 2014, filed 14 Nov 2014.